Drug intelligence / Profile preview

Choulingdan mixture

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Choulingdan mixture (CLDM) is an empirical clinical prescription that has been used for almost 30 years for the adjuvant treatment of acute lung injury (ALI). It is composed of 93 characterized ingredients, including flavonoids, organic acids, saponins, terpenoids, and tannins. CLDM improves ALI by significantly inhibiting pulmonary inflammation, pulmonary edema, and oxidative stress, primarily through the inhibition of the PI3K-AKT signaling pathway.

Other names: Choulingdan臭灵丹合剂

Beyond the preview

Go deeper on Choulingdan mixture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Choulingdan mixture.

Explore the full profile